Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

Georgina V. Long, Matteo S. Carlino, Anna J. Lomax et al.|The Lancet Oncology|2017

Cited by 247